Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulizer vs DPI LAMA/LABA in Symptomatic COPD
NCT07133880Phase 4Recruiting
- Sponsor
- University of Tennessee Graduate School of Medicine
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of revefenacin, formoterol, umeclidinium, vilanterol in chronic obstructive pulmonary disease (COPD), sponsored by University of Tennessee Graduate School of Medicine. Started Dec 2023; status: recruiting.
02
Drugs
revefenacinformoterolumeclidiniumvilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07133880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07133880.